Meglitinide analogues in adolescent patients with HNF1A-MODY (MODY 3)

Pediatrics

Volumn 133, Issue 3, 2014, Pages

  Becker, Marianne ^a   Galler, Angela ^a   Raile, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Children; HNF1A; Hypoglycemic episodes; Meglitinide analogues; MODY 3; Nateglinide; Repaglinide

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; NATEGLINIDE; REPAGLINIDE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ARTICLE; CASE REPORT; CHILD; DIABETES MELLITUS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSURIA; HEMOGLOBIN BLOOD LEVEL; HEPATOCYTE NUCLEAR FACTOR 1A MATURITY ONSET DIABETES OF THE YOUNG; HUMAN; HYPOGLYCEMIA; INCIDENTAL FINDING; MALE; MORNING DOSAGE; OBESITY; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; SCHOOL CHILD;

CHILDREN; HNF1A; HYPOGLYCEMIC EPISODES; MEGLITINIDE ANALOGUES; MODY 3; NATEGLINIDE; REPAGLINIDE;

ADOLESCENT; BENZAMIDES; CHILD; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE;

EID: 84895099425     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-2537     Document Type: Article

References (22)

1. Schober E, Rami B, Grabert M, et al DPVWiss Initiative of the German Working Group for Paediatric Diabetology. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. Diabet Med. 2009;26(5):466-473
2. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature. 1996;384(6608):455-458 (Pubitemid 26414660)
3. Vaxillaire M, Pueyo ME, Clément K, et al. Insulin secretion and insulin sensitivity in diabetic and non-diabetic subjects with hepatic nuclear factor-1alpha (maturity-onset diabetes of the young-3) mutations. Eur J Endocrinol. 1999;141(6):609-618 (Pubitemid 30064761)
4. Odom DT, Zizlsperger N, Gordon DB, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science . 2004;303(5662):1378-1381 (Pubitemid 38269432)
5. Isomaa B, Henricsson M, Lehto M, et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia. 1998;41 (4):467-473 (Pubitemid 28157419)
6. Hansen T, Eiberg H, Rouard M, et al. Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucosetolerant carrier of a P447L mutation. Diabetes. 1997;46(4):726-730 (Pubitemid 27143395)
7. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue KC. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2009;10(suppl 12):33-42
8. Scott LJ. Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs . 2012;72(2):249 -272
9. Dornhorst A. Insulinotropic meglitinide analogues. Lancet. 2001;358(9294):1709-1716 (Pubitemid 33124335)
10. Culy CR, Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs. 2001;61(11):1625-1660 (Pubitemid 32905281)
11. Cozma LS, Luzio SD, Dunseath GJ, Langendorg KW, Pieber T, Owens DR. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes Care. 2002;25(8):1271-1276 (Pubitemid 41071131)
12. Marshall V, Wilton L, Shakir S. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. Acta Diabetol. 2006 May; 43(1):6-13 (Pubitemid 43780163)
13. Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care. 2006;29(2):189-194 (Pubitemid 44121080)
14. Tripathy D, Carlsson AL, Lehto M, Isomaa B, Tuomi T, Groop L. Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia . 2000;43(12):1476-1483 (Pubitemid 32737205)
15. Panten U, Burgfeld J, Goerke F, et al. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochem Pharmacol. 1989;38(8):1217-1229 (Pubitemid 19101950)
16. Winkler M, Stephan D, Bieger S, Kühner P, Wolff F, Quast U. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands. J Pharmacol Exp Ther. 2007;322(2):701-708 (Pubitemid 47105784)
17. Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science. 2009;325(5940):607-610
18. Boileau P, Wolfrum C, Shih DQ, Yang T-A, Wolkoff AW, Stoffel M. Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha- deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturityonset diabetes of the young, type 3 (MODY3). Diabetes. 2002;51(suppl 3):S343-S348 (Pubitemid 35403414)
19. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 2004;64(12):1339-1358 (Pubitemid 38916346)
20. Kramer W, Müller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res. 1996;28(9):464-468 (Pubitemid 26343739)
21. Raptis SA, Hatziagelaki E, Dimitriadis G, Draeger KE, Pfeiffer C, Raptis AE. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man. Exp Clin Endocrinol Diabetes . 1999;107(6):350-355 (Pubitemid 29479090)
22. Awa WL, Thon A, Raile K, et al DPV-Wiss. Study Group. Genetic and clinical characteristics of patients with HNF1A gene variations from the German-Austrian DPV database. Eur J Endocrinol. 2011;164(4):513-520